Baxter and 5 More Medical Device Stocks Primed for a Comeback

• Shares of medical device companies have fallen this year due to concerns about the impact of new obesity medicines.
• The iShares U.S. Medical Devices ETF is down 13% this year, while the S&P 500 has climbed 14%.
• Major players in the sector, such as Abbott Laboratories and Baxter International, have seen significant declines in their share prices.
• Investors are worried that the new weight-loss drugs will lead to changes in Americans’ health, potentially reducing demand for medical devices.
• However, the exact impact of the obesity drugs on medical device companies remains uncertain.
• Opportunities for stock-picking exist in the medical device sector, as some companies have room to grow.
• Insulet and DexCom are two companies that have passed screening criteria and are down significantly in the current selloff.
• Other stocks that have passed the screen include Baxter, Penumbra, ResMed, and Zimmer Biomet Holdings.

The share prices of medical device companies have been falling this year due to concerns about the impact of new obesity medicines. The iShares U.S. Medical Devices ETF is down 13% this year, while the S&P 500 has climbed 14%. Major players in the sector, such as Abbott Laboratories and Baxter International, have seen significant declines in their share prices. Investors are worried that the new weight-loss drugs will lead to changes in Americans’ health, potentially reducing demand for medical devices. However, the exact impact of the obesity drugs on medical device companies remains uncertain. Despite the selloff, there are opportunities for stock-picking in the medical device sector. Insulet and DexCom are two companies that have passed screening criteria and are down significantly in the current selloff. Other stocks that have passed the screen include Baxter, Penumbra, ResMed, and Zimmer Biomet Holdings.